Document is current
Any future updates will be listed below
-
Authors
Terheyden, Jan Henrik
Gerhards, Johanna
Ost, Reglind A. D.
Wintergerst, Maximilian W. M.
Holz, Frank G.
Finger, Robert P.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Bonn
- License Information
-
More Information
Article History
Received: 20 March 2023
Accepted: 14 September 2023
First Online: 21 September 2023
Declarations
:
: This study protocol was reviewed and approved by the Institutional Ethics Committee, University Hospital Bonn, Germany, approval ID 130/16. Written informed consent obtained from all participants.
: Not applicable.
: JHT: Heidelberg Engineering, Optos, Zeiss, CenterVue, Novartis, Okko.JG: Heidelberg Engineering, Optos, Zeiss, CenterVue.RADO: Heidelberg Engineering, Optos, Zeiss, CenterVue.MWMW: Heidelberg Engineering, Optos, Carl Zeiss Meditec, CenterVue, Heine Optotechnik GmbH, Berlin-Chemie AG, Novartis Pharma GmbH,D-Eye Srl, Eyenuk Inc., ASKIN & CO GmbH, DigiSight Technologies.FGH: Acucela, Allergan, Apellis, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, CenterVue, Ellex, Roche/Genentech, Geuder, Grayburg Vision, Heidelberg Engineering, Kanghong, LinBioscience, NightStarX, Novartis, Optos, Pixium Vision, Oxurion, Stealth BioTherapeutics, Zeiss.RPF: Bayer, Ellex, Novartis, Novartis, Opthea, Alimera, Santhera, Roche/Genentech, CentreVue, Zeiss.
